Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences orders, deals and press releases
851 filed, newest first. Page 17 of 18.
Jul 2009
13 Jul · Business
Press release dated July 13, 2009, titled "Zydus Cadila and Karo Bio's research collaboration has generated promising lead compounds". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
4 Jun · Business
Press release dated June 04, 2009, titled "Zydus files IND application with the DCGI for 'ZYD1' - a novel candidate to treat Diabetes and Obesity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
5 May · Business
Press release dated May 05, 2009, titled "Zydus receives approval for Mycophenolate Mofetil tablets and capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
28 Apr · Business
Press release dated April 28, 2009, titled "Zydus Cadila's Total Income up by whopping 26% in FY 09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Apr · Business
Press release dated April 02, 2009, titled "Zydus files IND application with the USFDA for 'ZYT1' a novel candidate to treat dyslipidemia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
31 Mar · Business
Company has received final approval from USFDA to market Topiramate Tablets in different strengths of 25 mg., 50 mg., 100 mg., and 200 mg. In this regard the Company has submitted a press release dated March 31, 2009, titled "Zydus receives final approval for Topiramate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Mar · Business
Company has signed new drug discovery and development agreement with Eli Lilly to discover and develop new Cardiovascular medicines. In this regard the Company has submitted a press release dated March 30, 2009, titled "Zydus Cadila announces research collaboration to discover and develop new cardiovascular medicines". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Press release dated March 04, 2009, titled "Zydus Research Centre Receives AAALAC Accreditation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
27 Jan · Business
Press release dated January 27, 2009, titled "Zydus Cadila's Total Income up by 31% in Q3". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
1 Dec · Business
Hon'ble High Court of Gujarat at Ahmedabad has at the hearing held on October 23, 2008, approved the Composite Scheme of Arrangement between Carnation Nutra-Analogue Foods Limited ("Carnation") and Cadila Healthcare Limited ("Cadila") and Zydus Hospitals and Medical Research Private Limited ("ZHMRPL") and their respective shareholders and creditors ('Composite Scheme') for the transfer of the Consumer Products Division of Cadila into Carnation and amalgamation of ZHMRPL with Cadila.
Nov 2008
11 Nov · Business
Press release dated November 11, 2008, titled "Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
22 Oct · Business
Press release dated October 22, 2008, titled "Zydus Cadila registers 33% increase in Operating Net Profit in Q2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Business
Press release dated October 20, 2008, titled "Zydus receives approval for Risperidone Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Oct · Business
Filing of the IND application for ZYT1-a novel lipid lowering molecule with the DCGI. Designed and developed at the Company's R&D Centre, ZYT1 is a novel, anti-dyslipidemic agent which may provide an alternative to statins or be an add-on to statin therapy. Further the Company has submitted a copy of press release dated October 16, 2008 "Zydus files IND application for 'ZYT1' a novel candidate to treat dyslipidemia"shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Business
"The World Health Organization has approved Lyssavac N - the Purified Duck Embroyo Rabies Vaccine (PDEV) manufactured by the Company, for purchase by various United Nation Agencies. With this, the Company has becomes the first Indian Pharma Company and the Second Pharma Company in the world, to receive the WHO accreditation (prequalification) for rabies vaccine". Further the Company has submitted a copy of press release dated October 14, 2008, titled "Zydus Cadila becomes the 1st Indian Pharma company to receive WHO accreditation for Rabies Vaccine". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
23 Sep · Business
Meeting of the Equity Shareholders and Unsecured Creditors of Cadila Healthcare Limited as directed by the Hon'ble High Court of Gujarat at Ahmedabad was convened and held on September 18, 2008. Mr. Mukesh M. Patel, Chairman appointed for the meeting conducted the meeting as directed in the Minutes of Order of the Gujarat High Court dated August 13, 2008. The Composite Scheme was approved by the requisite majority of the Equity Shareholders and by unanimous consent of Unsecured Creditors present and voting either in person or by proxy or as authorized representatives. The said Composite Scheme shall now be presented for approval and consideration of the Hon'ble High Court of Gujarat at Ahmedabad.4 Sep · Business
Press release dated September 04, 2008, titled "Zydus receives USFDA approval for Ramipril Cabsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
21 Aug · Business
Further to the No-objection letter obtained from the stock exchanges, Cadila Healthcare Limited ('the Company') had filed a company application with the Hon'ble High Court of Gujarat on August 11,2008 for Composite Scheme of Arrangement between Carnation Nutra - Analogue Foods Limited and Cadila Healthcare Limited and Zydus Hospitals and Medical Research Private Limited and their respective equity shareholders and creditors.Subsequently, the Hon'ble High Court of Gujarat, by an order made on August 13, 2008 has directed that a meeting of the Equity Shareholders and Unsecured Creditors of the Company be convened and held on September 18, 2008 for the purpose of considering, and if thought fit, approving with or without modification(s), the Composite Scheme of Arrangement between Carnation Nutra - Analogue Foods Limited and Cadila Healthcare Limited and Zydus Hospitals and Medical Research Private Limited and their respective equity shareholders and creditors.12 Aug · Business
Press release dated August 12, 2008, titled "Zydus and WHO to develop next-generation biologicals to fight rabies". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Aug · Business
Press release dated August 01, 2008, titled "Zydus receives approval for Bromocriptine Mesylate Capsules. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
29 Jul · Business
Press release dated July 29, 2008, titled "Zydus Cadila Q1 Net profit up by 21%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Jul · Business
Board of Directors of the Company at its meeting held on July 04, 2008 has approved the modalities of the restructuring of its Consumer Products Division ("CPD') for the benefit of its shareholders. The Board has approved a Composite Scheme of Arrangement for demerger of the CPD of the Company into Carnation, which is a 61.56% listed subsidiary Company of the Company and merger of Zydus Hospitals and Medical Research Private Limited ("Zydus Hospitals") into the Company and the share entitlement / exchange ratios. This Scheme will be, subject to requisite consent, approval of the shareholders of all three Companies, the Hon'ble High Court of Gujarat, respective Stock Exchanges and other regulatory authorities. Further the Company has submitted a copy of press release dated July 04, 2008, titled "Cadila Healthcare to restructure its consumer business and create a single listed entity. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2008
16 Jun · Business
Press release dated June 16, 2008, titled "Zydus scores with first day launch of Venlafaxine Hydrochloride in the US".A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jun · Business
Company through its wholly owned subsidiary - Zydus Healthcare SA PTY. Ltd. is acquiring majority stake of 70% in Simayla Pharmaceuticals of South Africa. As per the agreement reached between the two companies, the remaining stake will be held by the promoter of the Company. In this regard Company has submitted a copy of press release dated June 09, 2008, titled "Zydus acquires majority stake in Simayla Pharmaceuticals of South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
30 May · Business
Press release dated May 30, 2008, titled "Zydus Cadila enters Spain, acquires Laboratorios Combix". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 May · Business
Press release dated May 26, 2008, titled "Zydus Cadila to market Benazepril in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 May · Business
Press release dated May 15, 2008, titled "New Product Approvals for Zydus Cadila from USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
29 Apr · Business
Press release dated April 29, 2008, titled "Zydus Cadila's Net Sales up by whopping 27% in FY 08". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
11 Mar · Business
Press release dated March 11, 2008, titled "Zydus and Nycomed expand scope of JV to create an API manufacturing hub for global supplies". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
15 Feb · Business
Press release dated February 15, 2008, titled "Zydus Cadila firms up presence in Oncology segment with Nudoxa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Feb · Business
Press release dated February 04, 2008, titled "Zydus Cadila and Karo Bio of Sweden sign research agreement for a novel drug to treat inflammatory diseases". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
31 Jan · Business
Press release dated January 31, 2008, titled "Zydus Cadila's Income up by 22.7% in Q3". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Jan · Business
Press release dated January 24, 2008, titled "Zydus Cadila and Prolong Pharmaceuticals ink pact for collaboration in Drug Discovery and Development". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
26 Oct · Business
Press release dated October 26, 2007, titled "Zydus Cadila registers 28% Income growth in Q2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
25 Sep · Business
Press release dated September 25, 2007, titled "Zydus Cadila receives USFDA approval for Hydroxychloroquine Sulfate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Sep · Business
Press release dated September 06, 2007, titled "Zydus Cadila receives USFDA approval for Carvedilol Tablets Launches product on the very same day". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
30 Aug · Business
Press release dated August 30, 2007, titled "Zydus Cadila files its 5th IND 'ZYH7' a novel drug candidate for treating dyslipidemia and metabolic disorders". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
31 Jul · Business
Press release dated July 31, 2007, titled "Zydus Cadila Q1 Net profit up by 27%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
25 Jun · Business
Press release dated June 25, 2007, titled "Zydus Cadila acquires Brazilian company Nikkho". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jun · Business
Zydus Cadila has entered into an agreement with TGL Enterprises LLC of United States to set up a joint venture company, Zydus Noveltech Inc to develop novel drug delivery based products12 Jun · Business
Press release dated June 12, 2007, titled "New Product Approvals for Zydus Cadila from USFDA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Jun · Business
"The Company has received tentative approval for Topiramate Tablets in the strength of 25 mg., 50 mg., and 200 mg. from USFDA". A copy of the press release dated June 06, 2007, titled "Zydus receives tentative approval for Topiramate tablets" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
15 May · Business
"Company has launched 'Slimona' new generation anti-obesity drug in India. Slimona (Rimonabant) is a selective CB1 Endocannabinoid (EC) receptor antagonist indicated for the treatment of obesity". A copy of the press release dated May 15, 2007, titled "Zydus Cadila, the first to launch revolutionary anti-obesity drug Slimona in India" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 May · Business
"The Company has signed Share Purchase Agreement for acquiring 50% equity shares of Sarabhai Zydus Animal Health Limited from its JV Partner Ambalal Sarabhai Enterprises Limited". A copy of the press release dated May 14, 2007, titled "Zydus Cadila buys out JV stake in Sarabhai Zydus Animal Health Ltd" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
26 Apr · Business
Press release dated April 26, 2007, titled "Zydus Cadila's Net Profit up by whopping 53% in FY 07". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Apr · Business
Press release dated April 20, 2007, titled "Zydus receives tentative approval for Losartan Potassium tablets". The details of the press release is as follows: "Zydus Cadila has received tentative approval for Losartan Potassium Tablets in the strengths of 25 mg, 50 mg and 100 mg from the USFDA. The branded sales of Losartan Potassium Tablets, which falls in the anti-hypertensive segment, is estimated at USD 817 million in 2006 as per NDC Health. The group now has 23 approvals since the commencement of filing process in FY 2003-04. Currently the group markets 9 generies through its subsidiary Zydus Pharmaceuticals (USA) Inc".19 Apr · Business
"The Company has acquired 100% Stake in Nippon Universal Pharmaceutical Limited, a privately held Company having its headquarter at Tokya, Japan". Further the Company has submitted a copy of the press release dated April 19, 2007, titled "Zydus Cadila acquires Nippon Universal, strengthens its presence in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2007
19 Mar · Business
"Company has received three product approvals from USFDA in quick succession to market Azathioprine Tablets 50 mg and tentative approvals for Divalproex Sodium Extended Release Tablets 250 mg and 500 mg and Venlafaxine Hydrochloride Tablets 25mg, 37.5 mg, 50 mg, 75 mg and 100 mg. The Company will market all the three drugs through its US Subsidiary Zydus Pharmaceuticals (USA) Inc". Further the Company has submitted a copy of press release dated March 17, 2007, titled "New Approvals strengthen Zydus' US product basket". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Mar · Business
Press release dated March 16, 2007, titled "Zydus Cadila acquires Liva Healthcare, enters the 1500 cr. derma market". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Press release dated March 12, 2007, titled "Zydus Cadila receives USFDA approval for Paroxetine Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.